Seek Returns

BNTX vs. RGEN: BioNTech vs. Repligen Stock Comparison

How do BioNTech (BNTX) and Repligen (RGEN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

BioNTech (BNTX) and Repligen (RGEN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BNTX is classified in Biotechnology while RGEN is classified in Life Sciences Tools & Services.

Repligen (RGEN) trades as ordinary local shares, while BioNTech (BNTX) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile comparison for BioNTech (BNTX) and Repligen (RGEN)
Profile ItemBNTXRGEN
NameBioNTech SE American Depositary ShareRepligen Corporation
Country/RegionGermanyUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyLife Sciences Tools & Services
GICS Sub-IndustryBiotechnologyLife Sciences Tools & Services
Market Capitalization21.70 billion USD11.09 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateOctober 10, 2019April 29, 1986
Security TypeADRCommon Stock

Price Performance

Cumulative Growth

BNTX
RGEN
GSPC
Loading price history…
BioNTech (BNTX) vs. Repligen (RGEN), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for BioNTech (BNTX) and Repligen (RGEN). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for BioNTech (BNTX) and Repligen (RGEN). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for BioNTech (BNTX) and Repligen (RGEN)
MetricBNTXRGEN
Total Return (1Y)-14.78%23.28%
Total Return (3Y, Annualized)-3.99%6.20%
Total Return (5Y, Annualized)-17.02%-8.41%

Risk Profile

Drawdown History

BNTX
RGEN
GSPC
Loading price history…
BioNTech (BNTX) vs. Repligen (RGEN), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for BioNTech (BNTX) and Repligen (RGEN). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for BioNTech (BNTX) and Repligen (RGEN)
MetricBNTXRGEN
Volatility (1Y, Annualized)47.44%46.73%
Beta (5Y)1.301.11
Max Drawdown (5Y)-78.10%-64.67%
Avg. Volume (3M)1.21M1.18M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
BNTX and RGEN are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for BioNTech (BNTX) and Repligen (RGEN)
MetricBNTXRGEN
Sharpe Ratio (1Y)-0.400.41
Sortino Ratio (1Y)-0.590.60

Profitability

ROE (TTM)

Both BioNTech (BNTX) at -8.14% and Repligen (RGEN) at -0.57% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

-8.14%

Max
109.18%
Q3
6.23%
BNTX
-8.14%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

-0.57%

Max
109.18%
Q3
6.23%
RGEN
-0.57%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
BioNTech (BNTX) vs. Repligen (RGEN): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Both BioNTech (BNTX) at -60.87% and Repligen (RGEN) at -1.47% report negative net margin values, usually indicating net losses over the period.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

-60.87%

Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
BNTX
-60.87%

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

-1.47%

Max
18.05%
Q3
4.78%
Median
0.00%
RGEN
-1.47%
Q1
-4.14%
Min
-17.05%
Loading chart…
BioNTech (BNTX) vs. Repligen (RGEN): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

BioNTech (BNTX) at 30.28% operates in the top operating margin quartile, ahead of Repligen (RGEN) at 6.19%, which runs around its industry’s norm.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

30.28%

Max
83.12%
BNTX
30.28%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.19%

Max
83.12%
Q3
14.77%
RGEN
6.19%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
BioNTech (BNTX) vs. Repligen (RGEN): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for BioNTech (BNTX) and Repligen (RGEN)
MetricBNTXRGEN
ROE (TTM)-8.14%-0.57%
ROA (TTM)-4.04%1.40%
Net Margin (TTM)-60.87%-1.47%
Operating Margin (TTM)30.28%6.19%
Gross Margin (TTM)76.73%53.77%

Growth

Revenue Growth

Both BioNTech (BNTX) at 4.32% and Repligen (RGEN) at 16.36% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
BioNTech (BNTX) vs. Repligen (RGEN): A comparison of their Revenue Growth across different time periods.

EPS Growth

Neither BioNTech (BNTX) nor Repligen (RGEN) reports a EPS growth value for this period, so a direct comparison isn't possible.

Loading chart…
BioNTech (BNTX) vs. Repligen (RGEN): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for BioNTech (BNTX) and Repligen (RGEN)
MetricBNTXRGEN
Revenue Growth (YoY)4.32%16.36%
Revenue Growth (3Y CAGR)-45.06%-2.70%
EPS Growth (YoY)----
EPS Growth (3Y CAGR)---35.73%

Financial Strength

Current Ratio (MRQ)

Both BioNTech (BNTX) at 8.55 and Repligen (RGEN) at 9.88 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.55

Max
25.13
Q3
12.13
BNTX
8.55
Median
5.52
Q1
2.47
Min
0.10

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.88

Max
25.13
Q3
12.13
RGEN
9.88
Median
5.52
Q1
2.47
Min
0.10
Loading chart…
BioNTech (BNTX) vs. Repligen (RGEN): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

BioNTech (BNTX) at 0.02 keeps leverage in the lower industry quartile, while Repligen (RGEN) at 0.33 runs a more typical debt-to-equity mix.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.02

Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
BNTX
0.02
Min
0.00

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.33

Max
1.42
Q3
0.65
RGEN
0.33
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
BioNTech (BNTX) vs. Repligen (RGEN): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for BioNTech (BNTX) and Repligen (RGEN)
MetricBNTXRGEN
Current Ratio (MRQ)8.559.88
Debt / Equity (MRQ)0.020.33
Net Debt / EBITDA---1.19

Dividends

Dividend Yield (TTM)

Neither BioNTech (BNTX) nor Repligen (RGEN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BNTX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

RGEN
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
BioNTech (BNTX) vs. Repligen (RGEN): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither BioNTech (BNTX) nor Repligen (RGEN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BNTX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

RGEN
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
BioNTech (BNTX) vs. Repligen (RGEN): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for BioNTech (BNTX) and Repligen (RGEN)
MetricBNTXRGEN
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

Neither BioNTech (BNTX) nor Repligen (RGEN) reports a P/E ratio value for this period, so a direct comparison isn’t possible.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
BNTX
--

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
RGEN
--
Loading chart…
BioNTech (BNTX) vs. Repligen (RGEN): Neither stock reports P/E ratio, so the chart shows available benchmark boxes without value markers.

P/S Ratio (TTM)

On P/S ratio, both BioNTech (BNTX) at 8.96 and Repligen (RGEN) at 13.77 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.96

Max
58.18
Q3
25.77
BNTX
8.96
Median
7.30
Q1
3.01
Min
0.01

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.77

Max
58.18
Q3
25.77
RGEN
13.77
Median
7.30
Q1
3.01
Min
0.01
Loading chart…
BioNTech (BNTX) vs. Repligen (RGEN): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

BioNTech (BNTX) at 1.09 sits in the lower P/B ratio quartile against book while Repligen (RGEN) at 4.70 is valued near its industry’s middle — BNTX is cheaper on assets, though weigh it against ROE and asset quality.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.09

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
BNTX
1.09
Min
-5.59

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.70

Max
13.53
Q3
6.54
RGEN
4.70
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
BioNTech (BNTX) vs. Repligen (RGEN): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for BioNTech (BNTX) and Repligen (RGEN)
MetricBNTXRGEN
P/E Ratio (TTM)----
P/S Ratio (TTM)8.9613.77
P/B Ratio (MRQ)1.094.70
Free Cash Flow Yield (TTM)-7.34%1.01%